This company seems to have been delisted
Reason: Rebranded as Talphera
Last recorded trade on: March 13, 2024
Source: https://www.fiercepharma.com/marketing/acelrx-becomes-talphera-adopting-new-name-reflect-pain-pivot
Reason: Rebranded as Talphera
Last recorded trade on: March 13, 2024
Source: https://www.fiercepharma.com/marketing/acelrx-becomes-talphera-adopting-new-name-reflect-pain-pivot
AcelRx Pharmaceuticals
ACRX
A$1.31
Share price
7.50%
Change (1 day)
45.39%
Change (1 year)
Categories
Earnings for AcelRx Pharmaceuticals (ACRX)
Earnings in 2023 (TTM): -A$15.37 Million
According to AcelRx Pharmaceuticals 's latest financial reports the company's current earnings are A$0.65 Million. In 2022 the company made an earning of A$87.49 Million, an increase over its 2021 earnings that were of -A$53.32 Million. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for AcelRx Pharmaceuticals from 2010 to 2023
Annual earnings
| Year | Earnings | Change |
|---|---|---|
2023 (TTM)  | -A$15.37 Million | -117.56% |
| 2022 | A$87.49 M | -264.1% |
| 2021 | -A$53.32 Million | -13.08% |
| 2020 | -A$61.35 Million | -24.16% |
| 2019 | -A$80.89 Million | 12.92% |
| 2018 | -A$71.64 Million | -9.7% |
| 2017 | -A$79.33 Million | 20.88% |
| 2016 | -A$65.63 Million | 82.71% |
| 2015 | -A$35.92 Million | -29.12% |
| 2014 | -A$50.68 Million | 42.38% |
| 2013 | -A$35.6 Million | -27.33% |
| 2012 | -A$48.98 Million | 66.59% |
| 2011 | -A$29.4 Million | 70.22% |
| 2010 | -A$17.28 Million |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 Cara Therapeutics
CARA | -A$95.4 Million | 510.40% | 🇺🇸 USA |
 Recro Pharma
REPH | A$5.71 M | -136.59% | 🇺🇸 USA |